相关实验视频
Updated: Jul 7, 2025

Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
患者对口服抗癌剂的坚持:对支持性干预的映射审查
Saima Ahmed1,2, Carmen G Loiselle1,2,3,4
1Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
口服抗癌药物 (OAAs) 需要更好的患者支持来坚持. 未来的干预措施应该整合四种模式 (行为,教育,医疗,技术),以理论为指导,以改善结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 口服抗癌剂 (OAAs) 的使用越来越多,需要改善患者对家庭治疗的支持.
- 有效的坚持干预措施对于优化OAA疗效和患者结果至关重要.
- 目前关于OAA坚持支持干预措施的证据需要综合,以确定差距并指导未来的研究.
研究的目的:
- 绘制有关支持口服抗癌药物 (OAAs) 坚持使用的干预措施的现有证据.
- 确定有关OAA坚持干预措施的文献上的差距.
- 为未来的OAA坚持支持研究和实践提供建议.
主要方法:
- 进行了全面的映射审查,搜索了四个主要数据库和2010年至2022年的灰色文献.
- 包括定量,定性,混合方法研究,论文,论文和报告;不包括协议和评论.
- 数据提取的重点是出版年,理论基础,研究设计,患者群体,干预类型和结果.
主要成果:
- 在选了3175个记录后,保留了120个出版物.
- 大多数研究是观察性 (39.2%) 或准实验性 (38.3%),很少是基于理论的 (17.5%).
- 干预措施通常包括一到两种模式 (63.7%),药物坚持主要通过自我报告或药房补充量来衡量.
结论:
- 需要更多以理论为导向的多模式干预 (行为,教育,医疗,技术) 来支持OAA的坚持.
- 未来的研究应该调查全面,定制干预措施的有效性,以优化与OAA相关的结果.
- 对于在家中管理OAAs的人来说,加强专业指导和患者支持至关重要.
更多相关视频
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Cancer Survival Analysis